Compare HP Inc (HPQ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs BIO-TECHNE Corp — how do they compare? HP Inc trades at $28.88 (market cap $27.25B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: HP Inc is far larger — about 2.4× BIO-TECHNE Corp's market cap, and HP Inc pays the higher dividend (4.03%). Which is the better fit depends on your goals.
| HPQ | TECH | |
|---|---|---|
Market Cap | $27.25B | $11.24B |
Sector | Technology | Health |
52-Week High | $30.05 | $72.29 |
52-Week Low | $18.20 | $43.31 |
Enterprise Value | $34.41B | $11.32B |
Dividend Yield | 4.03% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ stock trades at $30.05, up 6.64% in the past 24 hours, with a bullish technical signal from moving averages and oscillators. The company reported Q2 FY2026 revenue of $14.4B, up 9% year-over-year, and non-GAAP EPS of $0.86, beating expectations by 21%. HPQ maintains a dividend yield near 4% with consistent payouts, while valuation metrics like P/E of 11.13 and P/S of 0.49 suggest potential undervaluation relative to peers. Recent news highlights AI-driven cost savings and a premium product mix fueling growth.
Outlook: HPQ benefits from AI PC upgrade cycle optimism and margin expansion, but faces risks from PC shipment declines and competitive pressures. Analyst consensus is mixed with 29% buy ratings, yet the stock trades above the $22.00 average price target, indicating limited near-term upside. Investors should weigh strong cash flow generation against industry headwinds.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
